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Abstract
Background and Purpose: The purpose of this study was to assess plan quality and treatment time achievable
with the new VMAT optimization tool implemented in the treatment planning system Oncentra MasterPlan® as
compared to IMRT for Elekta SynergyS® linear accelerators.
Materials and methods: VMAT was implemented on a SynergyS® linear accelerator (Elekta Ltd., Crawley, UK) with
Mosaiq® record and verify system (IMPAC Medical Systems, Sunnyvale, CA) and the treatment planning system
Oncentra MasterPlan® (Nucletron BV, Veenendaal, the Netherlands). VMAT planning was conducted for three typical
target types of prostate cancer, hypopharynx/larynx cancer and vertebral metastases, and compared to standard
IMRT with respect to plan quality, number of monitor units (MU), and treatment time.
Results: For prostate cancer and vertebral metastases single arc VMAT led to similar plan quality as compared to
IMRT. For treatment of the hypopharynx/larynx cancer, a second arc was necessary to achieve sufficient plan
quality. Treatment time was reduced in all cases to 35% to 43% as compared to IMRT. Times required for
optimization and dose calculation, however, increased by a factor of 5.0 to 6.8.
Conclusion: Similar or improved plan quality can be achieved with VMAT as compared to IMRT at reduced
treatment times but increased calculation times.
Background
Volumetric modulated arc therapy (VMAT) allows irra-
diation with simultaneously varying dose rate, gantry
speed, collimator, and leaf positions. It has been first
introduced by Otto in 2008 [1] and implemented for
Varian linear accelerators as RapidArc® [2-8]. Various
treatment planning studies have been published, com-
paring RapidArc® and dynamic intensity modulated
radiation therapy (IMRT) or conventional stereotactic
treatments with regard to plan quality, delivery time,
and monitor units required per fraction dose
[2,3,7,9-19], using either in-house developed treatment
planning systems (TPS) or the Varian TPS Eclipse. For
Elekta linear accelerators volumetric modulated arc
t h e r a p yb e c a m ea v a i l a b l eu n d e rt h el a b e lV M A Ti n
2008. The only commercially available treatment plan-
ning system was ERGO++ (3D Line Medical Systems/
Elekta Ltd, Crawley, UK), which, however, requires
initial definition of sub-arcs and manual adaptation of
the multileaf collimator (MLC) before automatic weight
optimization and can therefore not be considered as a
fully inverse planning system [20-23]. Fully inverse treat-
ment planning systems for Elekta linear accelerators
have become commercially available only recently. A
few plan comparison studies have been published
[24-26] using the treatment planning system Pinnacle
(Philips Healthcare, Andover, MA). All of these studies
showed similar plan quality at substantially reduced
treatment times for VMAT as compared to IMRT. In
December 2009 a new VMAT optimization tool, imple-
mented in Oncentra MasterPlan® v3.3, was released
clinically, which allows VMAT optimization for Varian
and Elekta linear accelerators with a linac-vendor inde-
pendent planning system.
The aim of this study was to investigate the feasibility
of VMAT with the new commercial combination of
Oncentra MasterPlan® (Nucletron BV, Veenendaal, the
Netherlands) and SynergyS® linear accelerators (Elekta
Ltd, Crawley, United Kingdom). VMAT optimization was
performed for typical target types usually treated with
IMRT at our department and compared to standard
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units, and treatment time. Patients were selected for
whom treatment times required for IMRT are critical
due to possible intra-fractional organ movement or
patient discomfort and who therefore might benefit sub-
stantially from the advancement from IMRT to VMAT.
Methods
Linear accelerator and record and verify system
A SynergyS® linear accelerator with 6MV photons,
equipped with a BeamModulator™ head, an iViewGT™
electronic portal imaging device, and an on-board cone-
beam CT XVI is used for VMAT delivery. The Beam-
Modulator™ head has a multileaf collimator which
consists of 40 leaf pairs of 4 mm width at isocenter and
allows unrestricted leaf interdigitation. Fixed diaphragms
limit the maximum field size of 21 cm × 16 cm, and
there are no moveable jaws. Minimum and maximum
number of MU per degree of gantry rotation are 0.10
MU/° and 20.0 MU/° respectively, minimum MU per
cm leaf travel is 0.30 MU/cm, maximum gantry speed is
6.00 °/s. Maximum leaf speed is 2.4 cm/s, the dynamic
minimum leaf gap 0.14 cm, and the static minimum leaf
gap 0.0 cm. The maximum nominal dose rate is 500
MU/min. Seven fixed dose rate levels are available, each
h a l ft h ed o s er a t eo ft h en e x thigher level, continuous
variation is not possible. Actual dose rates may differ
from nominal dose rates by ±25%. During VMAT deliv-
ery the fastest combination of dose rate, gantry speed
and leaf speed is automatically selected by the linac con-
trol system Precise Desktop® 7.
Treatment planning system
Treatment planning is performed with Oncentra
MasterPlan® v3.3 SP1, released clinically in December
2009, on a 64 bit Windows system with 8 GB RAM and
8-core processor. For beam data modeling the above
mentioned VMAT specific parameters of the linac have
to be defined. Since the TPS only allows for 5 different
dose rates, two dose rates had to be omitted. We kept
the 5 higher and omitted the two lower dose rates,
because according to the literature the main advantage
of VMAT as compared to IMRT is the short treatment
time, which would be prolonged if higher dose rates
would be omitted. This is also in concordance with Bed-
ford’s recommendation not to use dose rates below 75
MU/min to a large extent due to instabilities of the
linac below 37 MU/min [27]. Since the linac automati-
cally selects the fastest combination of gantry speed, leaf
speed and dose rate, these parameters are only used to
ensure compliance with machine constraints and esti-
mate treatment time in the optimization. They are, how-
ever, not transferred to the linac and have therefore no
influence on the delivery.
For treatment planning, beams are set up in the Beam
Modeling module (BM), in which the treatment unit,
energy and collimator angle are defined by the user.
Gantry speed, leaf positions and dose rate are subject to
optimization, the collimator angle, however, is kept con-
stant at the predefined value for each arc. Other user
defined parameters for the optimization include start
gantry angle, rotation direction, arc length, gantry angle
spacing between subsequent control points (2° to 6°),
maximum delivery time, number of arcs, and con-
strained leaf motion in cm/°.
Optimization is performed in the Optimization Mod-
ule, which allows the user to choose between the IMRT
options “Intensity Modulation” (IM) with subsequent
leaf sequencing, and the direct machine parameter opti-
mization “Direct Step and Shoot” (DSS), and VMAT.
In DSS a fluence optimization with subsequent leaf
sequencing is performed for static fields for a few itera-
tions to get an initial guess for the segments. In the
next step, the gradients of the objective function are cal-
culated with respect to leaf positions and weights, allow-
ing direct optimization of deliverable MLC segments,
which leads to improved results as compared to IM
[28-30].
VMAT optimization starts with a fluence optimization
for gantry angle spacing of 24° and subsequent MLC
sequencing, generating 2 segments per gantry angle.
The segments are then spread out evenly and cloned to
achieve the required gantry angle spacing as defined by
the user. Based on this starting point a direct machine
parameter optimization is performed, taking machine
restrictions into account, followed by a final accurate
dose calculation and segment weight optimization. The
method is a successor of and very similar to the method
described in [31], where new segments are created by
linear interpolation instead of cloning.
Continuous delivery is discretized and approximated
by the calculation of static beams separated by 2° to 6°,
depending on the user defined gantry angle spacing.
The result of the accurate dose calculation is used as
starting point for an automatic second optimization run
to improve results [32]. For more than one arc, the dual
arc option is available, which groups the segments, such
that the required leaf movement is reduced, i.e. one arc
contains segments with leaves positioned more to the
left, and the other more to the right. Detailed informa-
tion about the optimizer has been published in [31].
Commissioning of the system combination of Oncen-
tra MasterPlan®, Mosaiq® and SynergyS® for VMAT has
been successfully completed with individual plan verifi-
cations within 3% dose tolerance and 3 mm distance to
agreement. Validation has been performed by absolute
2D-dosimetry using the 2D-array MatriXX
Evolution® (IBA
Dosimetry, Schwarzenbruck, Germany). A description of
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ever, is beyond the scope of this study and will be pub-
lished separately.
Treatment planning feasibility study
For a selection of patients who had undergone or were
currently under IMRT treatment at our department,
VMAT plans were optimized and compared to the
IMRT plans to assess plan quality achievable with
VMAT. The feasibility study was performed on three
patients with typical target geometries of head and neck
and prostate cancer, as well as spinal cord sparing irra-
diation of vertebrae.
1. A 64 year old patient with prostate cancer, pT3b,
pN0, cM0, R1, with a planning target volume (PTV)
of 424.1 cm
3 and a boost volume of 241.7 cm
3.T h e
PTV covered the prostatic fossa and the region of
seminal vesicles defined by pelvic CT with 8 mm
margin for setup, organ motion and delineation
uncertainties. Dose prescription was 60 Gy in 2 Gy
fractions to the average of the PTV, and 70 Gy in 2
Gy fractions to the boost volume. The bladder, rec-
tum and the femoral heads were delineated as organs
at risk (OAR). The volumes of rectum and bladder,
which were not overlapping with the PTV that was
extended by an additional 0.8 cm margin, were used
as help structures for optimization and evaluation of
plan quality, referred to as “rectum - PTV” and “blad-
der - PTV” respectively. The feasibility study was per-
formed for the first series only. Dose volume
objectives (DVO) based on dose prescription and
OAR tolerance doses are listed in table 1.
2. A 52 year old male patient with cancer of the hypo-
pharynx/larynx T4, N2c, M0, with 626.2 cm
3 PTV,
and 452.2 cm
3 boost volume. The definition of PTV
and organs at risk was according to literature [33].
Dose prescription was 60 Gy in 2 Gy fractions to the
average of the PTV, and 70 Gy in 2 Gy fractions to
the average of the boost volume. The spinal cord, the
brain stem, the parotids, the temporomandibular joint,
the lung, and the lenses were delineated as OAR. The
feasibility study was performed for the PTV only. Dose
volume objectives based on dose prescription and
OAR tolerance doses are listed in table 2.
3. A 70 year old female patient with metastases in
the lumbar vertebra, with a volume of 342.8 cm
3 of
the PTV and 60.7 cm
3 of the GTV. The PTV was
defined as the whole vertebral body with a 5 mm
margin, the definition of GTV based on tumour
mass identified by nuclear magnetic resonance
tomography. Dose prescription was 44 Gy to the
average of the PTV in fractions of 2.0 Gy and 55 Gy
to the average of the GTV volume in fractions of 2.5
Gy, treated as simultaneous integrated boost (SIB).
The spinal cord and the kidneys were delineated as
OAR. Dose volume objectives based on dose
Table 1 Treatment plan comparison for prostate cancer
Structure Parameter DVO Single arc IMRT
PTV D50% Uniform 60.0 Gy 59.9 Gy
H Dose 5.5 7.0
V95% 60 Gy 99.9% 97.2%
Normal Tissue D1% ≤ 60.0 Gy 60.0 Gy 59.9 Gy
D10% ≤ 30.0 Gy 29.9 Gy 31.7 Gy
D25% ≤ 15.0 Gy 17.5 Gy 17.7 Gy
Rectum D1% - 60.7 Gy 60.2 Gy
Rectum - PTV D1% ≤ 40.0 Gy 37.8 Gy 38.5 Gy
Bladder D1% - 61.5 Gy 62.2 Gy
Bladder - PTV D1% ≤ 30.0 Gy 47.4 Gy 47.4 Gy
Left Femoral Head D50% - 28.5 Gy 29.9 Gy
Right Femoral Head D50% - 29.8 Gy 28.9 Gy
Monitor Units MU/2.0 Gy - 695 687
Time Calculation - 16:30 min 2:52 min
Delivery - 4:45 min 11:00 min
DX% is the dose delivered to X% of the volume in Gy, V95% the volume
receiving 95% of the prescription dose in%, Homogeneity H = (D5% -D 95%)/
Daverage.
Table 2 Treatment plan comparison cancer for
hypopharynx/larynx
Structure Parameter DVO Dual Arc Single
Arc
IMRT
PTV D50% Uniform 60.0 Gy 60.5 Gy 59.7 Gy
H Dose 7.0 9.4 8.0
V95% 60 Gy 97.8% 95.4% 95.7%
Normal
Tissue
D1% ≤ 60 Gy 58.4 Gy 58.1 Gy 57.8 Gy
D20% ≤ 21 Gy 20.1 Gy 20.4 Gy 21.5 Gy
D60% ≤ 4 Gy 1.9 Gy 1.9 Gy 2.0 Gy
Left Parotid D50% ≤ 26 Gy 23.7 Gy 23.1 Gy 29.4 Gy
Right Parotid D50% ≤ 26 Gy 20.6 Gy 23.3 Gy 26.4 Gy
Spinal Cord D1 ccm ≤ 39 Gy 36.9 Gy 39.8 Gy 37.6 Gy
Brain Stem D1 ccm ≤ 43 Gy 34.4 Gy 41.5 Gy 36.9 Gy
Left Joint* D50% - 2.6 Gy 2.7 Gy 2.9 Gy
Right Joint* D50% - 2.3 Gy 2.2 Gy 2.5 Gy
Monitor
Units
MU/2.0 Gy - 715 552 799
Time Calculation - 33:10
min
16:30 min 4:52 min
Delivery - 5:00 min 2:08 min 14:15
min
*temporomandibular joint
DX% and D1 ccm are the doses delivered to X% of the volume and 1 cm
3
respectively, V95% the volume receiving 95% of the prescription dose in%,
Homogeneity H = (D5% -D 95%)/Daverage.
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table 3.
For all patients the normal tissue was defined as an
O A Rb ys u b t r a c t i n gt h eP T Vf r o mt h ep a t i e n to u t l i n e
and used during optimization to prevent high dose areas
outside the PTV.
Several planning studies have been published compar-
ing fluence modulation with subsequent leaf sequencing
IM and the direct aperture optimization DSS in Oncen-
tra MasterPlan®, showing clear advantage for DSS
[28-30]. Therefore, the reference IMRT plans were opti-
mized with DSS in this study. Seven equispaced beams
have been used in all IMRT plans.
For the optimization of VMAT plans, single arcs ranging
from 182° to 178° gantry angle with a gantry angle spacing
of 4° and the leaf motion constrained to 0.5 cm/° were
used. The collimator angle was set to 45° as suggested in
[34], except for the head and neck case for which the colli-
mator had to be set to 0° to ensure PTV coverage. Maxi-
mum delivery time was set to 150 s per arc for patient
number 1 and 2, and to 200 s per arc for patient number
3. If the plan quality achievable with single arc was not
comparable to IMRT, plans were re-optimized using the
dual arc option leaving gantry angle range and spacing
unchanged. Dose volume objectives were kept identical to
the IMRT plans. In addition to plan quality the times
required for planning and irradiation were compared. Cal-
culation times were measured from the start of the optimi-
zation until the end of the final dose calculation,
irradiation times were measured from the start of the first
beam until the end of the last beam.
Results
The feasibility study showed similar plan quality at
reduced delivery times and similar number of MU per
fraction for VMAT as compared to IMRT in all cases:
1 .F o rt h ep r o s t a t ec a s e ,s i n g l ea r cV M A Ts h o w e d
better dose homogeneity and target coverage, and
similar, mostly even lower dose to the organs at risk.
Time for optimization and dose calculation
increased by a factor of 5.8, treatment time was
reduced to 43%. Detailed information is given in
table 1. Figure 1 shows the dose distribution in
transversal CT-slices, figure 2 the respective dose
volume histograms (DVH).
2. For the case with cancer of the hypopharynx/larynx,
single arc VMAT showed similar target coverage and
better sparing of the parotids, but deteriorated homo-
geneity as compared to IMRT. Better overall plan
quality including target coverage, homogeneity inside
the PTV, as well as OAR sparing could be achieved
with dual arc VMAT. Even the relative volume of the
normal tissue, receiving doses between 20.0 Gy and
50.0 Gy is smaller in case of the dual arc treatment.
Only the relative volume of the normal tissue receiving
between 5.0 Gy and 20.0 Gy is slightly larger. Detailed
information is given in table 2. Figure 3 shows the
dose distribution for dual arc as compared to IMRT in
transversal slices, figure 4 the respective DVH. Seg-
ment shapes for a selected gantry angle are shown in
figure 5, illustrating the grouping of the segments into
arcs with respect to the leaf positions. For dual arc,
time for optimization and dose calculation increased
by a factor of 6.8, treatment time was reduced to 35%,
as compared to IMRT.
3. For the patient with metastases in the lumbar ver-
tebra, single arc VMAT showed similar plan quality
as compared to IMRT. Doses to the GTV were simi-
lar, median dose and D95% for the PTV higher, doses
t ot h ek i d n e yw e r ea l s oh i g h e rb u ts t i l lb e l o wt h e
tolerance and fulfilling the DVO used in optimiza-
tion. Time for optimization and dose calculation
increased by a factor of 5.0, treatment time was
reduced to 41%. Since patients with bone metastases
suffer from pain and are not able to keep the posi-
tion for a long time, the VMAT plan was considered
superior because of the reduced treatment time.
Detailed information is given in table 3. Figure 6
shows the dose distribution in transversal, sagittal
and coronal slices, figure 7 the respective DVH.
Patient 1 and 3 have actually been treated with VMAT
after successful completion of commissioning, patient 2
had already finished treatment.
Table 3 Treatment plan comparison for metastases of the
lumbar vertebra (SIB)
Structure Parameter DVO Single Arc IMRT
GTV D50% Uniform 55.0 Gy 55.0 Gy
H Dose 7.3 7.1
GTV V95% 55 Gy 95.6% 95.9%
PTV D95% ≥ 40.0 Gy 41.4 Gy 40.5 Gy
Normal Tissue D1% ≤ 40.0 Gy 41.3 Gy 42.6 Gy
D20% ≤ 15.0 Gy 13.6 Gy 8.0 Gy
D60% ≤ 5.0 Gy 1.8 Gy 1.3 Gy
Left Kidney D40% ≤ 10.0 Gy 9.4 Gy 7.8 Gy
Right Kidney D40% ≤ 10.0 Gy 9.0 Gy 5.3 Gy
Spinal Cord D1 ccm ≤ 45.0 Gy 41.7 Gy 41.1 Gy
Monitor Units MU/2.5 Gy - 698 736
Time Calculation - 13:50 min 2:45 min
Delivery - 4:30 min 11:00 min
DX% and D1 ccm are the doses delivered to X% of the volume and 1 cm
3
respectively, V95% the volume receiving 95% of the prescription dose in%,
Homogeneity H = (D5% -D 95%)/Daverage.
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The VMAT optimization tool implemented in Oncentra
MasterPlan® v.3.3 allows creating VMAT plans with
similar or better plan quality as compared to IMRT
which can be delivered in substantially reduced treat-
ment time on an Elekta SynergyS® linear accelerator. For
the treatment of prostate cancer and vertebral
metastases, the required plan quality could be achieved
with one single arc VMAT, which is in agreement with
the results published for other types of equipment
[4,18,24,35]. For the treatment of hypopharynx/larynx
cancer, however, single arc VMAT did not lead to suffi-
cient plan quality, reducing target homogeneity as com-
pared to IMRT and violating the DVO for the spinal
Figure 1 Dose distributions for prostate cancer. Comparison of dose distributions achieved with 7-field IMRT (left) and Single Arc VMAT
(right) on representative transversal (top) and sagittal (bottom) CT slices. The PTV is drawn in red, the bladder in orange, the rectum in maroon,
and the femoral heads in green. Isodose lines are shown in percent of the prescription dose, i.e. 60 Gy to the average of the PTV.
Figure 2 Dose volume histograms for prostate cancer. Comparison of dose volume histograms achieved with 7-field IMRT (dotted lines) and
Single Arc VMAT (solid lines). Plan quality is slightly better for VMAT, with better target coverage and homogeneity and lower OAR doses.
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Page 5 of 10Figure 3 Dose distributions for hypopharynx/larynx cancer. Comparison of dose distributions achieved with 7-field IMRT (left) and Dual Arc
VMAT (right) on representative transversal (top) and sagittal (bottom) CT slices. The PTV is drawn in red, the parotids in blue and purple, the
spinal cord in green, and the brain stem in bright blue. Isodose lines are shown in percent of the prescription dose, i.e. 60 Gy to the average of
the PTV.
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quality as compared to single arc VMAT but also to
IMRT, which also complies with publications to other
VMAT solutions [14,24,36]. The findings of Bertelsen
[25], who reported good results for single arc VMAT
for head and neck cancer using SmartArc® (Philips
Healthcare, Andover, MA) could not be confirmed. In
this case, however, plan comparison was performed for
simultaneous treatment of three target levels, which
requires certain dose heterogeneity inside the target.
The applicability of the system to simultaneous inte-
grated boost concepts has been demonstrated for the
treatment of vertebral metastases. In this case, a single arc
was sufficient to achieve the required plan quality. The
same concept can be applied for SIB treatments of other
target types like prostate or head and neck cancers. It
m i g h te v e nb ep o s s i b l et h a ts i n g l ea r ct r e a t m e n t sa r ei n
general suitable for SIB concepts due to the required dose
heterogeneity inside the target, which would also explain
the results of Bertelsen [25] mentioned above. This, how-
ever, remains to be investigated in a separate study.
In the VMAT solution implemented in Oncentra
MasterPlan® v3.3, segment shapes and weights are sub-
ject to optimization, which is one of the main differ-
ences to the treatment planning system ERGO++®: In
ERGO++® segment shapes have to be defined by the
Figure 4 Dose volume histograms for hypopharynx/larynx cancer. Comparison of dose volume histograms achieved with 7-field IMRT
(dotted lines) and Dual Arc VMAT (solid lines). Plan quality is slightly better for VMAT, with somewhat lower dose to the parotids.
Figure 5 Typical MLC positions resulting from Dual Arc optimization. In Dual Arc VMAT, segments are grouped into arcs such that leaf
travel is minimized during each rotation. In the example shown in this figure, arc 1 contains segments with leaves positioned more to the left,
arc 2 to the right of the field.
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weights are optimized.
The quality of the VMAT plans resulting from optimi-
zation in ERGO++® is therefore highly dependent on the
individual user’s experience in creating suitable segment
shapes. The VMAT solution implemented in Oncentra
MasterPlan® v3.3 in contrary does not require any user
input for the segment shapes. Segment shapes and
weights are resulting from the optimization process and
the resulting plan quality is therefore less dependent on
the individual user.
The number of monitor units per fraction in this
study was similar for VMAT and IMRT, a significant
reduction as reported for Varian linacs could not be
Figure 6 Dose distributions for metastases in the lumbar vertebra. Comparison of dose distributions achieved with 7-field IMRT (left) and
Single Arc VMAT (right) on representative transversal (top) and sagittal (bottom) CT slices. The PTV is drawn in red, the GTV in orange, the spinal
cord in green, and the kidneys in maroon. Isodose lines are shown in percent of the prescription dose, i.e. 55 Gy to the average of the GTV.
Figure 7 Dose volume histograms for metastases in the lumbar vertebra. Comparison of dose volume histograms achieved with 7-field
IMRT (dotted lines) and Single Arc VMAT (solid lines). Using the same dose volume objectives for optimization, higher doses to the PTV are
achieved with VMAT for almost identical GTV coverage and homogeneity and sparing of the spinal cord but somewhat higher dose to the
kidneys.
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already considerably lower than the ones reported for
Varian. Treatment times, however, could be substantially
reduced to 35% to 43% as compared to IMRT, whereas
calculation times were 5.0 to 6.8 times higher for
VMAT.
The combination of plan quality and treatment time
shows clear advantage of VMAT over IMRT: Treatment
time is a crucial factor especially for patients who suffer
from pain or are not able to keep a certain position for
a longer time, as it is the case e.g. for patients with
bone metastases, or for patients with significant internal
organ movement, e.g. patients with prostate cancer, for
which the actual delivered dose distribution might differ
significantly from the planned dose distribution due to
intra-fractional movement. In these cases even a single
arc leads to the required plan quality, allowing reducing
overall treatment time from 11 minutes to well below 5
minutes. For the patient with hypopharynx/larynx can-
cer the dual arc VMAT showed better plan quality at
only 33% of the treatment time, which reduces patient
discomfort in the rigid mask system. The reduction in
delivery time leads to better patient comfort and possi-
bly also quality of delivery, and simultaneously reduces
the workload and increases availability of the linac.
The only drawback found for VMAT as compared to
IMRT was the increased calculation time. This, however,
has no impact on patient treatment or on the workload
but is only affecting availability of the treatment plan-
ning station. Workload for the planner is virtually the
same for VMAT as for IMRT, since the steps of the
planning procedure, which require user interaction, like
definition of structures, beam setup, definition of DVO,
are the same in both cases. In the future calculation
times may be reduced using a processor with more than
8 cores or performing the dose calculation on the GPU
processor, as it will be implemented in the next version
of Oncentra MasterPlan®.
It could be shown that VMAT planning with Oncen-
tra MasterPlan® has the potential to produce better plan
quality requiring less delivery time as compared to
IMRT. However, dedicated planning studies should be
performed, varying the user definable parameters e.g.
maximum treatment time, number of arcs, and gantry
angle range, to identify the best parameter set to achieve
optimal combination of plan quality and treatment time
for each target type.
Conclusion
Oncentra MasterPlan® allows achieving comparable or
superior plan quality with VMAT as compared to
IMRT. Times required for optimization and dose calcu-
lation are increased, the number of monitor units per
fraction is similar, and treatment times are strongly
reduced.
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